Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin +/- Rucaparib in Residual TNBC or BRCA+ Breast Cancer
NCT01074970Phase 2Completed
- Sponsor
- Hoosier Cancer Research Network
- Start
- Feb 2010
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rucaparib in breast cancer (2 arms), sponsored by Hoosier Cancer Research Network. Primary endpoint: Disease Free Survival at 24 months. Started Feb 2010; status: completed.
02
Drugs
rucaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01074970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01074970.